Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05298904

Pro-active Genetic Testing in Kidney Transplant Patients

The purpose of this study is to determine the prevalence of genetic mutations that increase the risk of cancer and other medically actionable diseases in kidney transplant patients and to assess the impact of genetic testing on subsequent surveillance for cancer.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Kidney Transplant

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic Arizona

Scottsdale, Arizona, 85259, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Post transplant Kidney and Kidney Pancreas recipients.

Exclusion criteria

  • Simultaneous Liver Kidney Transplant.
  • Simultaneous Heart Kidney Transplant.
  • Non renal transplant history.

Treatment and study plan

Genetic Health Screen Panel

Diagnostic Test

This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).

Primary outcomes

  1. Genetic mutations of cancer

    Time frame: 1 year

    Number of subjects to have genetic mutations of cancer in kidney transplant patients receiving care at Mayo Clinic Arizona

Secondary outcomes

  1. The impact of genetic testing

    Time frame: 1 year

    Current guidelines for cancer screening have limitations, as its mostly age based. Immunosuppression can lead to a increased risk of cancer in the kidney transplant population.

    By utilizing a multi gene panel we'll look for the number subjects with positive findings and see how recommendations of care change vs standard of care as recommended by the National Comprehensive Cancer Network (NCCN). Genetic testing and family history may change the practice regarding cancer screening in subjects undergoing kidney transplant evaluation.

  2. Develop a Biorepository

    Time frame: 1 year

    Create a biorepository based on whole exome sequencing and clinical data for future analysis

Other outcomes

  1. Genetic mutations of cardiomyopathy

    Time frame: 1 year

    Prevalence of genetic mutations for cardiomyopathies in kidney transplant recipients

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2022
Primary completion
2037
Study completion
2038
First posted
Mar 28, 2022
Registry last updated
Jan 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.